Prot #M23‐696: A Phase 3b/4 Randomized, Open‐label, Efficacy Assessor Blinded Study, Comparing the Safety and Assessor Blinded Efficacy of Upadacitinib to Dupilumab in Subjects with Moderate to Severe Atopic Dermatitis (Level‐Up)

Project: Research project

Project Details

StatusFinished
Effective start/end date8/25/23 → 8/25/24

Funding

  • AbbVie Inc. (Prot #M23-696)